United States Drug Manufacturers - General news

22:07 11 Aug 2026

Market source Deals and strategy Main company 🇺🇸 United States

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

This article compares AbbVie and CVS Health as investment opportunities in 2026, highlighting their distinct business models and risk profiles. AbbVie, a biopharmaceutical giant, is favored for its focused operations and exciting growth trajectory, particularly with its immunology portfolio. CVS Health, an integrated healthcare …

ABBV main company

Sharemaestro market context Trend signal active 52 weeks +21.9% · Next-week setup positive 56.3%

21:51 11 Aug 2026

Stock Titan Market update Main company 🇺🇸 United States

Gilead Sciences (GILD) EVP converts 6,002 RSUs, with 2,908 shares withheld

Gilead Sciences, Inc.'s EVP, Keeley M Cain Wettan, reported the conversion of 6,002 restricted stock units (RSUs) into common stock on August 10, 2026. Of these, 2,908 shares were withheld at $133.06 per share to cover exercise price or tax liability. Following this transaction, …

GILD main company

Sharemaestro market context Price below Trend Line 52 weeks +15.5%

21:38 11 Aug 2026

MarketWatch Market update Main company 🇺🇸 United States

Pfizer Inc. stock underperforms Tuesday when compared to competitors

Pfizer Inc. (PFE) stock fell by 1.59% on Tuesday, closing at $26.62, and underperformed the broader market, as the S&P 500 Index and Dow Jones Industrial Average also saw declines. This drop ended a seven-day winning streak for the stock. The article highlights Pfizer's …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +12.0%

21:37 11 Aug 2026

MarketWatch Market update Main company 🇺🇸 United States

Biogen Inc. stock underperforms Tuesday when compared to competitors

Shares of Biogen Inc. (BIIB) fell 1.56% to $203.89 on Tuesday, underperforming the broader market. The S&P 500 Index and Dow Jones Industrial Average also experienced declines. This marked the second consecutive day of losses for Biogen's stock.

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.0%

21:14 11 Aug 2026

BioXconomy Market update Main company 🇺🇸 United States

aTyr, Biogen, City name legal chiefs

Several biopharma companies, including aTyr Pharma, Biogen, City Therapeutics, CytomX Therapeutics, and Sanofi, have recently appointed new chief legal officers or general counsels. These appointments reflect a focus on bolstering legal and compliance functions as these companies advance their therapeutic programs and expand their …

BIIB main company

Sharemaestro market context Trend signal active 52 weeks +50.0%

21:08 11 Aug 2026

MarketWatch Market update Main company 🇺🇸 United States

Gilead Sciences Inc. stock outperforms competitors on strong trading day

Gilead Sciences Inc. (GILD) saw its stock advance by 2.04% to $135.77 on Tuesday, outperforming the broader market which experienced a decline. The S&P 500 Index fell 0.32% and the Dow Jones Industrial Average fell 0.34% on the same trading day. Gilead Sciences Inc. …

GILD main company

Sharemaestro market context Price below Trend Line 52 weeks +15.5%

21:05 11 Aug 2026

finance.yahoo.com Market update Provider-linked mention 🇺🇸 United States

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

MacroGenics, Inc. ROCKVILLE, MD, Aug. 11, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Gilead Sciences, Inc. has exercised its option to obtain an exclusive license …

GILD mentioned

Sharemaestro market context Price below Trend Line 52 weeks +15.5%

21:05 11 Aug 2026

finance.yahoo.com Balance sheet Provider-linked mention 🇺🇸 United States

Absci Reports Business Updates and Second Quarter 2026 Financial and Operating Results

Absci Corporation Announced positive interim Phase 1 data from the HEADLINE™ trial of ABS-201 Completed $100 million underwritten offering, including $40 million strategic investment from Eli Lilly & Company Cash, cash equivalents, and marketable securities now sufficient to fund operations into the second half …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +69.9% · Next-week setup positive 58.2%

20:34 11 Aug 2026

finance.yahoo.com Deals and strategy Main company 🇺🇸 United States

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the …

AZN main company BMY mentioned

Sharemaestro market context Price below Trend Line 52 weeks +4.1%

20:27 11 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇺🇸 United States

NovelMed Advances NM5072 for Multiple Ocular Disorders

NovelMed Therapeutics Inc Key Highlights Multi-indication precedent: Biogen's approximately $5.6 billion acquisition of Apellis added EMPAVELI for PNH and SYFOVRE for GA, both of which contain pegcetacoplan. Primate proof of concept: A single intravitreal dose of NM5072 reduced CNV, hemorrhage, and retinal fibrosis in …

BIIB mentioned

Sharemaestro market context Trend signal active 52 weeks +50.0%

20:20 11 Aug 2026

Seeking Alpha Deals and strategy Main company 🇺🇸 United States

AstraZeneca held talks with Bristol-Myers through spring, summer - FT

AstraZeneca reportedly engaged in discussions with Bristol-Myers Squibb over the spring and summer regarding a potential acquisition. The talks were centered around AstraZeneca purchasing Bristol-Myers in a mostly stock-based deal at a premium.

BMY main company

Sharemaestro market context Trend signal active 52 weeks +38.5%

20:07 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Eli Lilly Scores Major Win in Weight-Loss Drug Race

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has secured U.K. approval for its once-daily weight-loss pill Foundayo, giving the drugmaker its first regulatory win for the treatment outside the U.S. and escalating its obesity battle with Novo Nordisk. The approval expands Lilly's …

LLY main company NVO mentioned

Sharemaestro market context Trend signal active 52 weeks +69.9% · Next-week setup positive 58.2%

19:38 11 Aug 2026

24/7 Wall St. Earnings Main company 🇺🇸 United States

Johnson & Johnson Nearing 52-Week High: Buy, Sell or Hold?

Johnson & Johnson (JNJ) is currently trading near its 52-week high, with analysts giving it a "Hold" rating due to its strong performance and pipeline balanced by valuation concerns and some declining product lines. While the company projects double-digit growth by the decade's end, …

JNJ main company

Sharemaestro market context Trend signal active 52 weeks +50.4%

19:14 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Merck (MRK) Wins FDA And EMA Review For Broader RSV Use In Children

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Merck (NYSE:MRK) said the FDA and EMA have accepted supplemental applications to expand ENFLONSIA for preventing RSV in young children at elevated risk. …

MRK main company

Sharemaestro market context Trend signal active 52 weeks +57.8%

19:05 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

Jim Cramer Highlights Arista Networks (ANET) Following Q2 Beat and 50% Rally

Arista Networks, Inc. (NYSE:ANET) posted $3.04 billion in total sales for Q2 2026, which represents a 37.7% year-over-year increase and beat Wall Street consensus estimates by $210 million. Non-GAAP earnings per share came in at $1.02, topping expectations by $0.13. The top-line expansion pulled …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +50.4%

18:38 11 Aug 2026

The Globe and Mail Deals and strategy Main company 🇺🇸 United States

Pfizer vs AbbVie: What's the Better Dividend Stock for Investors in 2026?

This article compares AbbVie (ABBV) and Pfizer (PFE) as dividend stock options for investors in 2026. While AbbVie offers solid financials, strong free cash flow, and consistent dividend growth despite a lower current yield, Pfizer provides a much higher immediate yield but comes with …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +12.0%

18:20 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

2 Stocks I Think Are Hands-Down Better Picks Than SpaceX Right Now

Space Exploration Technologies (NASDAQ: SPCX) has been perhaps the most talked-about stock on Wall Street since it completed the largest IPO ever in mid-June. Opinions on the company's prospects are divided. Some see an innovative company that has already disrupted the space travel industry …

LLY mentioned

Sharemaestro market context Trend signal active 52 weeks +69.9% · Next-week setup positive 58.2%

18:07 11 Aug 2026

Investing.com Earnings Main company 🇺🇸 United States

Gilead Sciences options activity points to institutional conviction on 2026 upside

Options traders are showing strong institutional conviction for upside in Gilead Sciences through 2026, with a high call bias and significant call spread activity. This suggests investors expect the stock to rise to the $135-$150 range, supported by strong technicals and fundamentals despite some …

GILD main company

Sharemaestro market context Price below Trend Line 52 weeks +15.5%

17:54 11 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% …

ABBV main company LLY mentioned JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +21.9% · Next-week setup positive 56.3%

17:52 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

Jim Cramer Weighs In on Sentiment Shifts Driving Accenture and Cognizant Rallies

On Monday's CNBC Mad Money episode, host Jim Cramer examined the top-performing stocks in the S&P 500, focusing on the dramatic turnaround in IT consulting leaders Cognizant Technology Solutions Corporation (NASDAQ:CTSH) and Accenture plc (NYSE:ACN). Addressing how market sentiment shifted around the "AI displacement …

JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +50.4%

17:50 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

Legend Biotech Gains 6% on Q2 Earnings Beat as Adjusted EPS Doubles Consensus

Quick Read LEGN surged 6% as Q2 revenue of $388M beat estimates and adjusted EPS of $0.16 doubled consensus, marking the company's first-ever profitable quarter. CARVYKTI net sales hit $657M, up 50%, with JNJ co-developer Janssen supporting management's target of over $5B in peak …

JNJ mentioned NVS mentioned BMY mentioned

Sharemaestro market context Trend signal active 52 weeks +50.4%

17:45 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge

BridgeBio Pharma BBIO reported a second-quarter 2026 loss of 78 cents per share, wider than the Zacks Consensus Estimate of a loss of 64 cents. Despite the miss, the figure improved compared to the year-ago loss of 95 cents. Revenues surged 120% year over …

PFE mentioned

Sharemaestro market context Price above Trend Line 52 weeks +12.0%

17:38 11 Aug 2026

Investing News Network Regulatory and legal Main company 🇺🇸 United States

Eli Lilly Soars Past US$1 Trillion as Novo Nordisk Stumbles

Eli Lilly's valuation has exceeded US$1 trillion, driven by strong sales of its GLP-1 weight-loss and diabetes treatments, Mounjaro and Zepbound. In contrast, Novo Nordisk's shares have declined due to slowing US sales and a high reliance on a single therapeutic category, despite both …

LLY main company

Sharemaestro market context Trend signal active 52 weeks +69.9% · Next-week setup positive 58.2%

17:00 11 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Pfizer (PFE) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 4, 2026 at 11:00 a.m. ET CALL PARTICIPANTS Chairman and Chief Executive Officer - Albert Bourla Chief Financial Officer - David Denton Incoming Interim Chief Financial Officer and Executive Vice President - Cecile Guegan Chief Scientific …

PFE main company

Sharemaestro market context Price above Trend Line 52 weeks +12.0%

16:26 11 Aug 2026

finance.yahoo.com Analyst action Provider-linked mention 🇺🇸 United States

European Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading

European equities traded in the US as American depositary receipts were tracking higher late Tuesday PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have …

NVO mentioned

Sharemaestro market context Price above Trend Line 52 weeks -5.7%

16:13 11 Aug 2026

Stock Titan Deals and strategy Main company 🇺🇸 United States

GSK plc (GSK) president reports acquisition of notional ADS in savings plan

GSK plc reported that its President, Maya Martinez-Davis, acquired 9.016 notional American Depositary Shares (ADS) at $52.9600 per ADS on August 7, 2026. This transaction occurred on the New York Stock Exchange and was part of her GSK Executive Supplemental Savings Plan account. The …

GSK main company

Sharemaestro market context Price below Trend Line 52 weeks +37.9% · Next-week setup positive 60.7%

16:12 11 Aug 2026

finance.yahoo.com Regulatory and legal Main company 🇺🇸 United States

Lilly Takes Its Weight-Loss Pill Battle Overseas

This article first appeared on GuruFocus. Eli Lilly and Co. (LLY, Financials), the developer of Foundayo and Zepbound, has received U.K. approval for Foundayo, the first approval for the weight-loss medication outside of the U.S. The The strategy pits Lilly directly against Novo Nordisk's …

LLY main company NVO mentioned

Sharemaestro market context Trend signal active 52 weeks +69.9% · Next-week setup positive 58.2%

16:00 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

Tecan Group AG (TCHBF) (H1 2026) Earnings Call Highlights: Strategic Progress and Market ...

This article first appeared on GuruFocus. Release Date: August 11, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Tecan Group AG (TCHBF) delivered solid above-market growth in both segments, with group sales up …

NVS mentioned

Sharemaestro market context Trend signal active 52 weeks +29.7% · Next-week setup positive 57.5%

15:04 11 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

Hedge Funds are Bullish on AstraZeneca PLC (AZN)

AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug …

AZN main company

Sharemaestro market context Price below Trend Line 52 weeks +4.1%

14:48 11 Aug 2026

finance.yahoo.com Earnings Main company 🇺🇸 United States

MRK Stock Up 5.6% in a Month as Estimates Fall: Buy, Hold or Sell?

Merck's MRK stock is up 5.6% in a month. The key reason for the increase was the strong second-quarter 2026 performance. Merck beat estimates for both earnings and sales in the second quarter. Revenues in the second quarter increased 5% to $16.61 billion as …

MRK main company AZN mentioned

Sharemaestro market context Trend signal active 52 weeks +57.8%

14:41 11 Aug 2026

BigGo Finance Market update Main company 🇺🇸 United States

Kolchinsky Warns Ban on Chinese Biotech Deals Would Hand Pipeline to Novartis

A debate in Boston featured RA Capital founder Peter Kolchinsky and Ginkgo Bioworks CEO Jason Kelly discussing whether the U.S. should ban in-licensing of drug assets from China. Kelly argued the U.S. has significant leverage due to its pharmaceutical revenue share, while Kolchinsky warned …

NVS main company

Sharemaestro market context Trend signal active 52 weeks +29.7% · Next-week setup positive 57.5%

14:41 11 Aug 2026

TradingView Earnings Main company 🇺🇸 United States

Do Options Traders Know Something About AstraZeneca Stock We Don't?

Options traders are showing significant interest in AstraZeneca (AZN) stock, with high implied volatility for the Jan. 15, 2027 $115.00 Call, suggesting expectations of a major price movement. Despite this, AstraZeneca currently holds a Zacks Rank #4 (Sell), and analysts have recently lowered earnings …

AZN main company

Sharemaestro market context Price below Trend Line 52 weeks +4.1%

14:40 11 Aug 2026

seekingalpha.com Market update Provider-linked mention 🇺🇸 United States

These stocks have some of Wall Street’s lowest short interest

[short sale] abluecup Stocks including Apple, Alphabet, Exxon Mobil, and JPMorgan are among the companies with relatively low short interest, according to a screen of stocks with market capitalizations above $2B. The screen includes stocks with short interest between 1% and 2% of shares …

LLY mentioned JNJ mentioned

Sharemaestro market context Trend signal active 52 weeks +69.9% · Next-week setup positive 58.2%

14:36 11 Aug 2026

seekingalpha.com Earnings Provider-linked mention 🇺🇸 United States

Polen International Equity adds NOK, MUFG; exits AIVAF, RNMBF among Q2 moves

Polen International Equity Strategy outperformed the MSCI ACWI ex-US Index in the second quarter of 2026, returning 21.59% gross and 21.35% net of fees, respectively, versus 14.49% for the benchmark. During the quarter, the fund initiated new positions in ASPEED Technology, Ryohin Keikaku (RYKKF …

AZN mentioned

Sharemaestro market context Price below Trend Line 52 weeks +4.1%

14:20 11 Aug 2026

finance.yahoo.com Deals and strategy Provider-linked mention 🇺🇸 United States

A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?

Quick Read BioCryst hit its first full year of profitability in 2025, with Q2 2026 revenue up 34% to $218 million, fueling acquisition speculation. Takeda (TAK) tops the buyer rankings as navenibart directly threatens its Takhzyro franchise; AstraZeneca (AZN) ranks second through its Alexion …

NVS mentioned AZN mentioned AMGN mentioned SNY mentioned

Sharemaestro market context Trend signal active 52 weeks +29.7% · Next-week setup positive 57.5%

14:12 11 Aug 2026

finance.yahoo.com Earnings Provider-linked mention 🇺🇸 United States

J&J Trading Above 200- & 50-Day SMAs: Buy, Sell or Hold the Stock?

Johnson & Johnson JNJ stock has been trading above both its 50-day and 200-day simple moving averages (SMAs) since mid-June. Trading above the 200-day SMA indicates that the stock's longer-term trend has turned positive, while staying above the 50-day SMA suggests that shorter-term momentum …

LLY mentioned JNJ mentioned GILD mentioned

Sharemaestro market context Trend signal active 52 weeks +69.9% · Next-week setup positive 58.2%